S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   312.04 (-0.73%)
AAPL   127.29 (-1.26%)
MSFT   212.96 (-0.03%)
FB   251.63 (+2.44%)
GOOGL   1,730.63 (-0.02%)
AMZN   3,103.58 (-0.76%)
TSLA   827.07 (-2.12%)
NVDA   514.92 (-2.48%)
BABA   242.79 (-0.08%)
CGC   33.52 (-3.18%)
GE   11.35 (-2.66%)
MU   80.57 (-0.90%)
AMD   88.25 (-2.80%)
T   29.19 (-0.34%)
NIO   56.13 (-7.79%)
F   9.87 (-2.95%)
ACB   11.93 (-0.25%)
BA   204.89 (-2.39%)
DIS   171.14 (-1.32%)
NFLX   498.38 (-0.50%)
GILD   63.36 (+1.54%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   312.04 (-0.73%)
AAPL   127.29 (-1.26%)
MSFT   212.96 (-0.03%)
FB   251.63 (+2.44%)
GOOGL   1,730.63 (-0.02%)
AMZN   3,103.58 (-0.76%)
TSLA   827.07 (-2.12%)
NVDA   514.92 (-2.48%)
BABA   242.79 (-0.08%)
CGC   33.52 (-3.18%)
GE   11.35 (-2.66%)
MU   80.57 (-0.90%)
AMD   88.25 (-2.80%)
T   29.19 (-0.34%)
NIO   56.13 (-7.79%)
F   9.87 (-2.95%)
ACB   11.93 (-0.25%)
BA   204.89 (-2.39%)
DIS   171.14 (-1.32%)
NFLX   498.38 (-0.50%)
GILD   63.36 (+1.54%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   312.04 (-0.73%)
AAPL   127.29 (-1.26%)
MSFT   212.96 (-0.03%)
FB   251.63 (+2.44%)
GOOGL   1,730.63 (-0.02%)
AMZN   3,103.58 (-0.76%)
TSLA   827.07 (-2.12%)
NVDA   514.92 (-2.48%)
BABA   242.79 (-0.08%)
CGC   33.52 (-3.18%)
GE   11.35 (-2.66%)
MU   80.57 (-0.90%)
AMD   88.25 (-2.80%)
T   29.19 (-0.34%)
NIO   56.13 (-7.79%)
F   9.87 (-2.95%)
ACB   11.93 (-0.25%)
BA   204.89 (-2.39%)
DIS   171.14 (-1.32%)
NFLX   498.38 (-0.50%)
GILD   63.36 (+1.54%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   312.04 (-0.73%)
AAPL   127.29 (-1.26%)
MSFT   212.96 (-0.03%)
FB   251.63 (+2.44%)
GOOGL   1,730.63 (-0.02%)
AMZN   3,103.58 (-0.76%)
TSLA   827.07 (-2.12%)
NVDA   514.92 (-2.48%)
BABA   242.79 (-0.08%)
CGC   33.52 (-3.18%)
GE   11.35 (-2.66%)
MU   80.57 (-0.90%)
AMD   88.25 (-2.80%)
T   29.19 (-0.34%)
NIO   56.13 (-7.79%)
F   9.87 (-2.95%)
ACB   11.93 (-0.25%)
BA   204.89 (-2.39%)
DIS   171.14 (-1.32%)
NFLX   498.38 (-0.50%)
GILD   63.36 (+1.54%)
Log in
NASDAQ:MYOK

MyoKardia Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$224.91
0.00 (0.00 %)
(As of 11/17/2020)
Add
Compare
Today's Range
$224.91
Now: $224.91
$224.91
50-Day Range
$222.81
MA: $224.61
$224.91
52-Week Range
$42.65
Now: $224.91
$225.00
VolumeN/A
Average Volume752,969 shs
Market Capitalization$11.99 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.84
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California.
MyoKardia logo

MarketRank

Overall MarketRank

0.73 out of 5 stars

Medical Sector

973rd out of 1,480 stocks

Pharmaceutical Preparations Industry

459th out of 612 stocks

Analyst Opinion: 1.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900
Employees318

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.56 million
Book Value$8.79 per share

Profitability

Net Income$-276,210,000.00

Miscellaneous

Market Cap$11.99 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MyoKardia (NASDAQ:MYOK) Frequently Asked Questions

Is MyoKardia a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MyoKardia in the last twelve months. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MyoKardia stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYOK, but not buy additional shares or sell existing shares.
View analyst ratings for MyoKardia
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than MyoKardia?

Wall Street analysts have given MyoKardia a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MyoKardia wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is MyoKardia's next earnings date?

MyoKardia is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for MyoKardia
.

How were MyoKardia's earnings last quarter?

MyoKardia, Inc. (NASDAQ:MYOK) issued its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.16.
View MyoKardia's earnings history
.

What price target have analysts set for MYOK?

11 brokerages have issued 12 month price targets for MyoKardia's stock. Their forecasts range from $86.00 to $225.00. On average, they expect MyoKardia's share price to reach $207.40 in the next year. This suggests that the stock has a possible downside of 7.8%.
View analysts' price targets for MyoKardia
or view Wall Street analyst' top-rated stocks.

Who are some of MyoKardia's key competitors?

What other stocks do shareholders of MyoKardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MyoKardia investors own include NVIDIA (NVDA), Micron Technology (MU), Pfizer (PFE), CVS Health (CVS), Gilead Sciences (GILD), AbbVie (ABBV), The Walt Disney (DIS), Johnson & Johnson (JNJ), Exelixis (EXEL) and Raytheon Technologies (RTX).

Who are MyoKardia's key executives?

MyoKardia's management team includes the following people:
  • Mr. Tassos Anastasios E. Gianakakos, Pres, CEO & Director (Age 47, Pay $987.02k)
  • Mr. Taylor C. Harris, Chief Financial Officer (Age 44, Pay $604.47k)
  • Dr. Robert S. McDowell, Chief Scientific Officer (Age 62, Pay $579.19k)
  • Mr. Jake B. Bauer, Chief Bus. Officer (Age 41, Pay $547.2k)
  • Mr. William C. Fairey Jr., Chief Commercial Officer & Exec. VP (Age 54, Pay $905.02k)
  • Dr. Leslie Leinwand, Co-Founder
  • Dr. Christine E. Seidman, Co-Founder (Age 67)
  • Dr. Jonathan G. Seidman, Co-Founder
  • Dr. James A. Spudich, Co-Founder (Age 78)
  • Michelle Corral, Exec. Director of Corp. Communications & Investor Relations

What is MyoKardia's stock symbol?

MyoKardia trades on the NASDAQ under the ticker symbol "MYOK."

What is MyoKardia's stock price today?

One share of MYOK stock can currently be purchased for approximately $224.91.

How big of a company is MyoKardia?

MyoKardia has a market capitalization of $11.99 billion and generates $33.56 million in revenue each year. The biotechnology company earns $-276,210,000.00 in net income (profit) each year or ($4.38) on an earnings per share basis. MyoKardia employs 318 workers across the globe.

What is MyoKardia's official website?

The official website for MyoKardia is www.myokardia.com.

How can I contact MyoKardia?

MyoKardia's mailing address is 1000 SIERRA POINT PARKWAY, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.